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Purpose: Dalfampridine extended-release (ER) tab-
lets 10 mg BID have been approved for use in
improving walking in people with multiple sclerosis
(MS). This subgroup analysis evaluated the effects of
dalfampridine ER 5 and 10 mg BID on distance
walked, as assessed using the 6-minute walk (6MW)
test.
Methods: This analysis of data from a randomized,
placebo-controlled, double-blind study (N ¼ 430)
included only the 153 patients with 6MW data
available. Participants (aged 18–70 years) were ran-
domly assigned in a 1:1:1 ratio to receive dalfampri-
dine ER 5 or 10 mg or placebo, BID for 4 weeks. The
6MW was used for assessing walking distance at
baseline and 2 weeks after the start of treatment at
the 26 study sites that were able to perform this test.
Participants were administered the 12-item MS Walk-
ing Scale (MSWS-12), a patient-reported measure of
the impact of MS on walking. Post hoc outcomes
included the percentages of patients who achieved an
increase from baseline in 6MW distance of Z20%
and who achieved a minimal clinically important
difference (MCID) from baseline in 6MW distance,
deﬁned as Zþ55 m. Changes from baseline in
walking speed (MSWS-12) were compared, stratiﬁed
by subgroup that achieved Z20% versus o20%
improvement on the 6MW. The correlation between
change in walking speed over time and subgroup
(by change in distance walked) was evaluated.2780The tolerability of dalfampridine was assessed based
on the prevalence of treatment-emergent adverse
events (TEAEs).
Findings: In the post hoc analysis, the percentage of
patients with an improvement in 6MW distance that
met or exceeded the MCID was signiﬁcantly greater
with dalfampridine ER 10 mg BID relative to placebo
(37.3% vs 12.2%; nominal P ¼ 0.004). Similarly, the
percentage with an improvement in 6MW distance of
Z20% was signiﬁcantly greater with dalfampridine
10 mg BID relative to placebo (45.1% vs 14.3%;
nominal P o 0.001). Regardless of treatment alloca-
tion, improvement in MSWS-12 was signiﬁcantly
greater in the subgroup that achieved a Z20%
improvement on the 6MW compared with the sub-
group with o20% improvement (mean changes,
–15.5 vs –7.2; nominal P ¼ 0.041). The prevalences
and types of TEAEs were consistent with those
reported in previous studies.
Implications: Based on the MCID for 6MW, the
use of dalfampridine ER 10 mg BID but not 5 mg BID
was associated with statistically signiﬁcant and clin-
ically meaningful improvements in walking relative to
placebo. The correlation between improvement onVolume 37 Number 12
A. Applebee et al.MSWS-12 and the 20% increase in 6MW distance
suggests that an improvement on MSWS-12 is clin-
ically relevant. These results, although highlighting
a lack of efﬁcacy of dalfampridine ER 5 mg
BID, suggest that the 10-mg BID dose is effective for
improving walking speed, as observed on short timed-
walk tests, and for increasing distance walked over
longer timed-walk periods. ClinicalTrials.gov identi-
ﬁer: NCT01328379. (Clin Ther. 2015;37:2780–2787)
& 2015 The Authors. Published by Elsevier HS
Journals, Inc.
Key words: 4-aminopyridine, 6-minute walk test,
ambulation, dalfampridine, multiple sclerosis, subgroup
analysis.
INTRODUCTION
Mobility impairment is common among patients with
multiple sclerosis (MS). Thus, it may not be surprising
that 70% of people with MS consider walking
difﬁculty as the most challenging aspect of the dis-
ease.1 Based on consistent changes in walking speed
in 2 pivotal studies,2,3 the use of dalfampridine
extended-release (ER) tablets (also known as
prolonged-release fampridine in Europe and as fam-
pridine modiﬁed- or sustained-release elsewhere) 10
mg BID for improving walking in people with MS has
been approved by the US Food and Drug Adminis-
tration.4 Dalfampridine ER is a broad-spectrum in-
hibitor of voltage-gated potassium channels, with a
putative mechanism of action of improving action-
potential conduction in the demyelinated axons that
are characteristic of MS.5
To fulﬁll a postmarketing regulatory commitment,
a study was performed to evaluate the efﬁcacy and
safety proﬁle of dalfampridine ER 5 mg BID, relative
to the approved dose of 10 mg BID, to those of
placebo was performed.6 The primary efﬁcacy end
point of the original study, change from baseline on
the timed 25-foot walk (T25FW) test at 4 weeks after
the start of treatment, was not signiﬁcantly different
between either of the active treatment groups and the
placebo group. However, in a post hoc analysis of
mean data from all study visits, walking speed was
signiﬁcantly increased in the 10-mg BID dose group
compared with that in the placebo group (nominal
P ¼ 0.014).6 Additionally, in a subgroup analysis,
the change from baseline in walking distance, as
assessed using the 6-minute walk (6MW) test,7 wasDecember 2015a prespeciﬁed secondary end point. A signiﬁcant
improvement in 6MW distance occurred in the
10-mg BID dose group, but not in the 5-mg BID dose
group, versus the placebo group (nominal P values,
0.014 and 0.308, respectively).
In this report, we expand on the results obtained
using the 6MW, further evaluate the effects of dal-
fampridine ER 5 and 10 mg BID on walking distance,
and explore the relationship between these objective
assessments and patient-reported walking outcomes.PATIENTS AND METHODS
Study Design
A detailed description of the patient selection and
methodology in this study has been previously pub-
lished.6 In brief, in this randomized, double-blind,
placebo-controlled, parallel-group study, after a
1-week screening period, participants were randomly
assigned, in a 1:1:1 ratio, to receive dalfampridine ER
5 or 10 mg or placebo, BID for 4 weeks. The study
was performed in accordance with the revised Decla-
ration of Helsinki. The protocol was approved by the
appropriate institutional review boards or independ-
ent ethics committees, and all patients provided
written informed consent.
Eligible participants were 18 to 70 years of age,
had been diagnosed with MS, and had MS-related
walking impairment but with ambulatory ability
sufﬁcient for completing the T25FW. A washout
period of at least 4 weeks before screening was
required in participants who had previously been
taking dalfampridine.Efficacy Assessments
The study was performed at 65 sites in the United
States, of which 26 were appropriate for administering
the 6MW, which was used for assessing walking
distance at baseline and at 2 weeks after the start of
treatment. The 6MW was performed on a 30.48-m
(100-ft) walkway, with the starting line and turn-
around points clearly marked, and participants were
instructed to walk as far and as fast as possible, back
and forth, for 6 minutes, without rest or encourage-
ment.7 The 6MW and the T25FW were administered
by an evaluator blinded to other clinical and safety
data on each patient, including each patient’s self-
report on the 12-item Multiple Sclerosis Walking Scale
(MSWS-12).82781
Clinical TherapeuticsBefore the administration of the 6MW, participants
were administered the MSWS-12,8 a multi-item scale
that enables patients to self-rate the impact of MS on
their walking during the preceding 2 weeks. It assesses
a range of walking-related functions and addresses the
quality of walking as well as the need for assistive
devices.8 Responses on the MSWS-12 are ratings on a
5-point Likert-type scale (from 1 ¼ not at all to 5 ¼
extremely), and the scores are transformed to a range
of 0 to 100, with greater scores indicating greater
impact on walking.
Tolerability Assessment
Safety proﬁle and tolerability measures included the
prevalences of treatment-emergent adverse events
(TEAEs), vital sign measurements, clinical laboratory
tests, and electrocardiography.
Statistical Analysis
A sample size of 135 patients per group was
calculated as being needed for 90% power to detect
a difference of 0.16 ft/sec in the primary efﬁcacy end
point (T25FW) between dalfampridine ER 10 mg BID
and placebo. This determination was based on pre-
viously observed differences between dalfampridine
ER 10 mg BID and placebo and used an assumed SD
of 0.40 ft/sec2,3.
Data from patients with data from 6MW assess-
ments available from baseline and week 2 of treatment
were included in this analysis. Treatment effects
(6MW) were compared using ANOVA, with terms
for treatment and baseline for the prespeciﬁed secon-
dary end point. Two types of post hoc responder
analyses were used for addressing the potential clinical
meaningfulness of change in 6MW distance. A change
in walking distance of 55.06 m (95% CI, 30.62–
79.51) (180.64 ft [95% CI, 100.46–260.86]) on the
6MW was previously estimated as the minimal clin-
ically important difference (MCID), using the Ex-
panded Disability Status Scale score as an anchor.9
The initial analysis of response was performed using
this criterion, although it may be considered
potentially inappropriate to apply across a wide
range of walking deﬁcits; the baseline walking
distances in the individuals in this study ranged from
23.8 to 521.2 m, with a mean of 259.0 m. The
criterion of a þ55.06-m change would therefore
represent an improvement of 21.3% in the average
patient, but would be a 231.3% improvement in the2782slowest patient and 10.6% in the fastest. Based on
previous work indicating that a 20% improvement on
the T25FW was clinically meaningful,10 the same
criterion was adopted for the second post hoc
analysis of response. Thus, the percentages of
patients who achieved an improvement of Z55.06
m, and the percentages who achieved a Z20%
improvement, on the 6MW at 2 weeks relative to
baseline were determined and compared across
treatments using the Cochran-Mantel-Haenszel test.
To examine further the clinical relevance of the
20% threshold, the changes from baseline in MSWS-
12 score were compared between the subgroup that
showed a Z20% improvement on the 6MW versus
the subgroup with o20% improvement, using
ANOVA. Because earlier studies reported that results
on the 6MW were strongly correlated with results
from assessments of ambulatory dysfunction in MS,
including the T25FW,7,11,12 an additional post hoc
analysis was performed to determine whether change
in walking speed over time is correlated with change
in distance walked. These correlations were assessed
using Pearson correlation coefﬁcients.
RESULTS
Patients
The baseline characteristics and disposition of the
patients who completed the 6MW are shown in
Table I and Figure 1, respectively. Demographic and
clinical characteristics at baseline were similar among
the treatment groups. Across groups, the mean age
varied from 52.0 to 53.9 years. The distribution of
Expanded Disability Status Scale scores was 5.0 to
5.1, which was comparable to that in the full study
population (4.7–4.8).6 At baseline, the mean 6MW
distance across groups ranged from 256.5 to 262.4 m
(841.5–860.9 ft).
Efficacy
The mean change from baseline in 6MW distance
at 2 weeks of treatment was signiﬁcantly greater with
the 10-mg BID dose (þ39.2 m [þ128.6 ft]), but not
with the 5-mg BID dose (þ23.4 m [þ76.8 ft]),
compared with placebo (þ12.7 m [þ41.7 ft]; nominal
P values, 0.014 and 0.308, respectively).6 On post hoc
analysis of the 6MW distance, the percentages of
patients who had improvements that met or
exceeded the estimated MCID relative to placebo
were 26.4% and 37.3% with the 5- and 10-mg BIDVolume 37 Number 12
Table I. Baseline demographic and clinical characteristics of the patients who completed the 6MW.
Variable
Dalfampridine ER
Placebo (n ¼ 49) P5 mg BID (n ¼ 53) 10 mg BID (n ¼ 51)
Age, mean (SD), y 52.0 (9.6) 53.9 (9.3) 53.8 (8.9) 0.510
Female, no. (%) 45 (84.9) 35 (68.6) 37 (75.5) 0.147
Race, no. (%) 0.053
White 38 (71.7) 44 (86.3) 40 (81.6)
Black/African American 15 (28.3) 5 (9.8) 9 (18.4)
Other 0 2 (3.9) 0
EDSS score, mean (SD) 5.0 (1.5) 5.0 (1.4) 5.1 (1.5) 0.976
Walking speed (T25FW), ft/sec 0.728
Mean (SD) 2.63 (0.91) 2.81 (1.07) 2.73 (1.41)
Median (range) 2.6 (0.6–5.2) 2.8 (0.8–5.1) 2.5 (0.4–6.2)
6MW distance, ft 0.956
Mean (SD) 841.5 (328.5) 842.6 (322.9) 860.9 (428.6)
Median (range) 864.0 (174.0–1700.0) 900.0 (78.0–1510.0) 794.0 (100.0–1710.0)
MSWS-12 score 0.182
Mean (SD) 66.0 (21.2) 57.7 (27.8) 64.7 (24.2)
Median (range) 68.8 (12.5–100.0) 58.3 (0.0–97.9) 72.9 (8.3–97.9)
6MW ¼ 6-min walk test; EDSS ¼ Expanded Disability Status Scale; ER ¼ extended release; MSWS-12 ¼ 12-item Multiple
Sclerosis Walking Scale; T25FW ¼ timed 25-ft walk test.
A. Applebee et al.doses, respectively, versus 12.2% with placebo (Figure 2),
with a dose response apparent in the 10-mg BID
dose group only (nominal P ¼ 0.004). Additionally,
the percentages of patients who achieved a Z20%
increase in 6MW distance were 28.3% and 45.1% with
dalfampridine ER 5 and 10 mg BID relative to placebo
(14.3%) (Figure 2), with only the 10-mg BID dose
showing signiﬁcance compared with placebo (nominal
P o 0.001).
Regardless of treatment allocation, the subgroup
that achieved aZ20% increase in 6MW distance was
observed to have had a signiﬁcantly greater improve-
ment in mean MSWS-12 score compared with the
subgroup that had o20% improvement in walking
distance (mean change, –15.5 vs –7.2; nominal P ¼
0.041) (Figure 3).
The change from baseline in 6MW distance was
correlated with change on the T25FW across treat-
ment groups (Table II), although the strength of the
correlation varied to some extent with the magnitude
of change observed in each treatment group.December 2015Safety Profile
A total of 58.8% of the participants with 6MW
data experienced Z1 TEAE, with a similar overall
prevalence among all 3 treatment groups (Table III).
The most commonly reported treatment-related
TEAEs across all treatment groups included headache,
dizziness, nausea, insomnia, and urinary tract infec-
tion, but no clear patterns were observed in this
subpopulation. There were no clinically meaningful
changes in vital sign measurements or on electro-
cardiography by treatment group.
DISCUSSION
Previously, we reported that treatment with dalfam-
pridine ER 10 mg BID, but not 5 mg BID, was
associated with increased walking distance on the
6MW relative to placebo (39.2 m [128.6 ft] vs 12.7
m [41.7 ft]; nominal P ¼ 0.014).6 This effect was seen
in the subset of patients evaluated with this test
despite the fact that the primary efﬁcacy end point
of the study, a single time-point assessment of change2783
Randomized
N = 430
Dalfampridine-ER 5 mg
n = 144
Placeboa
n = 142
Dalfampridine-ER 10 mg
n = 143
Treated (Safety Population)
Dalfampridine-ER 5 mg
n = 143
Placeboa
n = 136
Dalfampridine-ER 10 mg
n = 136
Full Analysis Population
Dalfampridine-ER 5 mg
n = 53
Placeboa
n = 49
Dalfampridine-ER 10 mg
n = 51
6MW Subgroup
Figure 1. Patient disposition showing subgroup-analysis population of patients who completed the 6-minute
walk (6MW) test after treatment with dalfampridine extended release (ER) or placebo. aOne patient
was randomized but did not receive treatment. Results from the full analysis population were
reported by Yapundich et al.6
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2784from baseline in walking speed on the T25FW, did not
reach statistical signiﬁcance with either dose of dal-
fampridine ER relative to placebo. These ﬁndings
suggest that longer walking tests, such as the 6MW,
may be more sensitive for detecting the treatment
effects of dalfampridine ER, although further evalua-
tion over a longer treatment duration is needed for
determining the long-term effects of dalfampridine ER
on walking distance.
Expanding on our previous primary results,6 we
report that 45% of the patients treated with
dalfampridine ER 10 mg BID had an increase in
distance walked of Z20% relative to baseline, and
that 37% of patients had an increase in walking
distance relative to baseline that met or exceeded the
previously estimated MCID of 55.06 m (180.64 ft). In
contrast, among patients treated with dalfampridine
ER 5 mg BID, only 28% had an increase in walking
distance of Z20%, and in 26%, the MCID was
exceeded. These ﬁndings corroborate our previous
conclusion that the approved dose, 10 mg BID, is
the minimal dose effective for improving walking
in patients with MS.6 The safety proﬁle in thisVolume 37 Number 12
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the 6-minute walk (6MW) test, after
2 weeks of treatment with dalfampri-
dine extended release (ER) or placebo.
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Table II. Associations between changes from baseline in
completed the 6MW after 2 weeks of treatmen
Parameter
Dalfamp
5 mg BID (n ¼ 53)
Change in 6MW, ft
Mean (SD) þ76.8 (198.8)
Median (range) þ67 (–620 to þ670)
Change in T25FW, ft/sec
Mean (SD) 0.33 (0.50)
Median (range) 0.28 (–0.53 to þ2.03)
T25FW vs 6MW, correlation
coefﬁcient
0.62 (P o 0.0001)
6MW ¼ 6-min walk test; ER ¼ extended release; T25FW ¼ tim
A. Applebee et al.
December 2015subpopulation was consistent with that reported in the
full study population.6
Although a 20% change in walking speed, as
measured using the T25FW, has been supported by
the ﬁndings from a number of studies as being
clinically meaningful,10 the clinical relevance of a
Z20% improvement on the 6MW has not been
established in patients with MS. However, in this
study, the mean change in MSWS-12 score in the
subgroup of patients withZ20% improvement on the
6MW was –15.5 compared with –7.2 in the subgroup
witho20% improvement, suggesting that this thresh-
old may be clinically relevant because patients per-
ceive that such a change has an impact on their
walking ability. These results parallel the observations
in the full analysis population (N ¼ 415), in which a
Z20% increase in average walking speed on the
T25FW was associated with a similar improvement
in mean MSWS-12 scores (–15.8) compared with
o20% improvement (–6.6).6 Additionally, the
estimated 55.06 m MCID represented 21.6% of the
mean baseline distance in this substudy. This
consistency across analyses supports the concept that
aZ20% improvement in 6MW distance likely reﬂects
a clinically meaningful change.
An important limitation of this study was that it
was performed in a subpopulation; because the 6MWwalking distance and walking speed in patients who
t with dalfampridine or placebo.
ridine ER
Placebo (n ¼ 49)10 mg BID (n ¼ 51)
þ128.6 (154.7) þ41.7 (163.5)
þ150 (–190 to þ472) þ40 (–383 to þ600)
0.36 (0.46) 0.18 (0.51)
0.33 (–0.45 to þ1.45) 0.19 (–1.12to þ1.97)
0.64 (P o 0.0001) 0.47 (P ¼ 0.0007)
ed 25-ft walk test.
2785
Table III. Tolerability of 4 weeks of treatment
with dalfampridine. Data are given as
number (%) of patients.
Parameter
Dalfampridine ER
Placebo
(n ¼ 49)
5 mg
BID
(n ¼ 53)
10 mg
BID
(n ¼ 51)
Any TEAE 32 (60.4) 30 (58.8) 28 (57.1)
Most common* TEAEs
Headache 7 (13.2) 7 (13.7) 5 (10.2)
Nausea 7 (13.2) 5 (9.8) 2 (4.1)
Insomnia 4 (7.5) 5 (9.8) 2 (4.1)
Fall 4 (7.5) 1 (2.0) 3 (6.1)
Dizziness 3 (5.7) 5 (9.8) 2 (4.1)
Dyspepsia 3 (5.7) – 1 (2.0)
Pain 3 (5.7) – 1 (2.0)
Paresthesia 2 (3.8) 4 (7.8) 2 (4.1)
Urinary tract
infection
2 (3.8) 3 (5.9) 2 (4.1)
Balance disorder 2 (3.8) 2 (3.9) 3 (6.1)
Nasopharyngitis 1 (1.9) 3 (5.9) –
Pain in extremity – 5 (9.8) –
Dry mouth – 3 (5.9) –
ER ¼ extended release; TEAE ¼ treatment-emergent
adverse event.
*Prevalence ofZ5% in any treatment group, by Medical
Dictionary for Regulatory Activities preferred term.
Clinical Therapeuticsprotocol requires a 100-ft hallway, only a subset of
study sites were appropriate for administering the test.
Despite this limitation, in this post hoc analysis, the
percentage of patients who achieved improvement in
walking distance was signiﬁcantly greater in the group
treated with dalfampridine ER 10 mg BID relative to
placebo, and more than one third of the patients
achieved the estimated MCID of 55.06 m (180.64 ft).
However, that MCID was estimated in a population
that had an overall level of disability that was lesser
than that in the current study, and the MCID was for
deterioration of walking ability; it is not clear whether
the MCID would also apply to an improvement in
walking distance. A threshold of the percentage
change in walking distance may be more clinically
meaningful than an absolute MCID value in dis-
tance because a percentage increase can represent a2786clinically relevant change across a broader range
of baseline values based on disability level. The
ﬁndings with regard to MSWS-12 further support a
20% threshold; regardless of treatment allocation,
the subgroup with a Z20% improvement in walk-
ing distance had a signiﬁcantly greater improve-
ment on the MSWS-12 compared with that in the
subgroup that had a o20% improvement on the
6MW. Although the percentage of patients whose
6MW was improved by Z20% was numerically
greater with dalfampridine ER 5 mg BID relative to
placebo, the difference was not statistically signiﬁ-
cant, supporting the appropriateness of 10-mg-BID
dosing for improvement in walking in patients
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